Zenapax®
Company
Protein Design Laboratory / Hoffman LaRoche
Use
Prevention of acute kidney transplant rejection
Features
noninfectious recombinant vaccine
NIH Contribution
Use of an antibody to the IL-2 receptor for treating malignancy and autoimmune disorders.
Approval Type
FDA
HHS Institute/Agency
NCI
Inventor(s)
T. Waldman
Year
1997
Tech Cat
Biologic
![L-057-1989 L-057-1989](/sites/default/files/styles/large/public/images/showcase/29186/zenapax-52.jpg?itok=Ns2iZl4M)